Daehwa gets Canada patent for oral paclitaxel
Published: 2009-10-29 06:56:00
Updated: 2009-10-29 06:56:00
Daehwa Pharm said on October 26 that it has recently won Canada patent covering the oral form of widely used cancer drug paclitaxel, which is normally administered through injection, following its patent acquisition in several countries, including China and Russia.
The patent covers "formulati...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
